Rob Surgical, the company responsible for designing and developing the new Bitrack System to universalise high precision surgery, has closed a €5 million investment round with the holding Scranton Enterprises to fund the final phase of the project and launch the product on the market. Osborne Clarke and RCD law firms provided advice throughout the process.
This investment will allow us to obtain CE certification in 30 months.
The Bitrack System will be an alternative to the current laparoscopy surgical robot Da Vinci, and will be an improvement on what is currently available in terms of efficiency. "Our value proposition that differentiates us from other surgical robots is based on three cornerstones: high precision benefiting the patient, superior usability for the surgeon and a significant total cost of ownership reduction benefiting hospitals", explains Jaume Amat, CEO of Rob Surgical and president of CataloniaBio & HealthTech.
Photo: Bitrack prototype in operation with animal models - © Rob Surgical
Comments